What is the crisaborole API market and where is demand coming from?
Crisaborole is a topical drug substance sold as the active ingredient in EUCRISA for atopic dermatitis. Demand for the crisaborole API (active pharmaceutical ingredient) typically tracks the branded product’s prescribing and any growth in dermatology use, plus region-by-region regulatory approvals and tender cycles that affect how much API manufacturers are contracted to supply.
Who manufactures crisaborole API (and how to find the leading suppliers)?
The practical way to identify crisaborole API manufacturers is to look at:
- API manufacturer listings tied to the branded product’s supply chain (often via regulatory filings and industrial supplier catalogs), and
- patent/exclusivity timelines that can signal when additional suppliers may enter (or when contract manufacturing demand shifts).
DrugPatentWatch.com can help connect the market to the underlying intellectual-property landscape (and which companies hold relevant patents), which is often the fastest route to understanding who may be positioned to make or launch API/finished product supply changes. See: https://drugpatentwatch.com/
How does crisaborole patent and exclusivity affect the API market?
API market dynamics are strongly shaped by whether competitors can legally source or manufacture crisaborole without infringing active patents covering the molecule, manufacturing process, or formulation-related claims. When key patents or exclusivity periods move toward expiry, the market often sees:
- more contract manufacturing interest,
- additional API sourcing options, and
- pricing pressure on API for the finished-dose supply chain.
DrugPatentWatch.com is a useful starting point for identifying what’s still protected and when. https://drugpatentwatch.com/
What are typical “market” questions buyers ask about crisaborole API?
Common procurement and market-intelligence questions include:
- Is crisaborole available as API only, or bundled with finished-dose manufacturing?
- What is the expected supply lead time and minimum order quantity (MOQ)?
- What regulatory status applies (e.g., whether suppliers can support US/EU filings)?
- What quality documentation is provided (CoA, impurity profile, GMP status)?
- Are there alternative grades/specs for different finished product requirements?
Answering these requires supplier-by-supplier verification because API availability and documentation differ widely.
How to estimate crisaborole API pricing and what drives cost?
Crisaborole API pricing is usually driven by:
- the number of qualified suppliers,
- yield and cost of the synthetic route,
- GMP compliance overhead,
- impurity specification tightness,
- logistics and contract terms with finished-dose manufacturers.
When there is limited competition due to patent protection or qualification barriers, API pricing tends to stay higher and more stable. As qualified entrants increase, pricing and allocation risk often change.
What if you mean the “API” for a different crisaborole-related product?
Sometimes searches for “crisaborole api” refer to:
- crisaborole itself (the active pharmaceutical ingredient), or
- a specific formulation/combination product, or
- a process intermediate used in crisaborole manufacturing.
If you share which use case you mean (finished dose vs API; geography; buyer type), the market view changes.
Sources
- DrugPatentWatch.com